Potential Medical Use of Fullerenols After Two Decades of Oncology Research

Abstract

Fullerenes are carbon molecules that are found in nature in various forms. They are composed of hexagonal and pentagonal rings that create closed structures. Almost 4 decades ago, fullerenes were identified in the form of C60 and C70, and following the award of the Nobel Prize in Chemistry for this discovery in 1996, many laboratories started working on their water-soluble derivatives that could be used in different industries, including pharmaceutical industries. One of the first fullerene forms that was the focus of different research groups was fullerenol, C60(OH) n ( n = 2-44). Both in-vitro and in-vivo studies have shown that polyhydroxylate fullerene derivatives can potentially be used as either antioxidative agents or cytostatics (depending on their co-administration, forms, and concentration/dose) in biological systems. The current review aimed to present a critical view of the potential applications and limitations of fullerenols in oncology, as understood from the past 2 decades of research.

Effects of fullerene C60 on liver tissue in liver ischemia reperfusion injury in rats undergoing sevoflurane anesthesia

“…Because it has been reported that aggregates form after a while after preparing a solution with polyhydroxylated fullerene. Dynamic light scattering of C 60 (OH)′ solutions revealed the formation of fullerene aggregates at concentrations as high as 40 mg/mL [ 35 ]. Despite this high resolution, low stability is a concern.…”